News Releases

All Releases
View Summary OncoGenex Pharmaceuticals Announces Appointment of John A. Bencich as Vice President and Chief Financial Officer
Aug 7, 2014
PDF 9.9 KB Add to Briefcase
View Summary OncoGenex to Report Financial Results for Second Quarter 2014 on August 7, 2014
Jul 24, 2014
PDF 9.6 KB Add to Briefcase
View Summary OncoGenex Announces Cedar™ Clinical Trial Evaluating Apatorsen in Combination with Chemotherapy in Advanced Squamous Cell Lung Cancer is Now Open for Enrollment
Jul 1, 2014
PDF 14.6 KB Add to Briefcase
View Summary OncoGenex Pharmaceuticals Announces Pricing of $24 Million Underwritten Registered Direct Offering
Jun 26, 2014
PDF 10.4 KB Add to Briefcase
View Summary OncoGenex Pharmaceuticals, Inc. Reports Financial Results for First Quarter 2014
Apr 30, 2014
PDF 17.2 KB Add to Briefcase
View Summary OncoGenex to Report Financial Results for First Quarter 2014 on April 30, 2014
Apr 28, 2014
PDF 9.6 KB Add to Briefcase
View Summary OncoGenex Announces Top-Line Survival Results of Phase 3 SYNERGY Trial Evaluating Custirsen for Metastatic Castrate-Resistant Prostate Cancer
Apr 28, 2014
PDF 13.6 KB Add to Briefcase
View Summary OncoGenex Announces Fast Track Designation Granted for Custirsen in Combination with Cabazitaxel/Prednisone as Second-line Chemotherapy in Phase 3 AFFINITY Trial of Men with Metastatic Castrate-Resistant Prostate Cancer
Apr 23, 2014
PDF 12.4 KB Add to Briefcase
View Summary OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2013
Mar 11, 2014
PDF 17.9 KB Add to Briefcase
View Summary OncoGenex to Report Financial Results for Fourth Quarter and Year-Ended 2013 on March 11, 2014
Feb 25, 2014
PDF 9.7 KB Add to Briefcase
View Summary OncoGenex Announces Target Number of Events Reached in Phase 3 SYNERGY Trial of Custirsen in Metastatic Castrate-Resistant Prostate Cancer
Feb 11, 2014
PDF 12.7 KB Add to Briefcase
View Summary OncoGenex to Present at Leerink Global Healthcare Investor Conference
Feb 6, 2014
PDF 9.2 KB Add to Briefcase
View Summary OncoGenex Announces Update on Phase 3 SYNERGY Trial Evaluating Custirsen in Men with Metastatic Castrate-Resistant Prostate Cancer
Nov 19, 2013
PDF 10.7 KB Add to Briefcase
View Summary OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Third Quarter 2013 and Addresses Key Questions from Investors on Quarterly Conference Call
Nov 7, 2013
PDF 18.3 KB Add to Briefcase
View Summary OncoGenex to Present at Credit Suisse Healthcare Investor Conference
Nov 5, 2013
PDF 9.2 KB Add to Briefcase
View Summary OncoGenex to Report Financial Results for Third Quarter 2013 and Address Key Questions from Investors on November 7, 2013
Oct 30, 2013
PDF 11.7 KB Add to Briefcase
View Summary OncoGenex Announces that the Rainier Clinical Trial Evaluating Apatorsen (OGX-427) in Combination with ABRAXANE® plus Gemcitabine in Patients with Metastatic Pancreatic Cancer is Now Open for Enrollment
Aug 29, 2013
PDF 13.7 KB Add to Briefcase
View Summary OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for Second Quarter 2013
Aug 8, 2013
PDF 20.8 KB Add to Briefcase
View Summary OncoGenex Pharmaceuticals to Present at Upcoming Investor Conference
Aug 7, 2013
PDF 8.9 KB Add to Briefcase
View Summary OncoGenex Announces that the Spruce™ Clinical Trial Evaluating OGX-427 in Combination with Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer is Now Open for Enrollment
Aug 1, 2013
PDF 14.1 KB Add to Briefcase
Showing 61-80 of 389 Page: 1 2 3 4 5 6 7 8 ... 20  Previous 20 | Next 20
Add to Briefcase = add release to Briefcase